

Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment



Ioly Kotta-Loizou^{*,†}, Spyridon N. Vasilopoulos[†],
Robert H.A. Coutts[‡] and Stamatios Theocharis[†]

^{*}Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London SW7 2AZ, United Kingdom; [†]First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece; [‡]Geography, Environment and Agriculture Division, Department of Biological and Environmental Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, United Kingdom

Abstract

Hu-antigen R (HuR) is an RNA-binding posttranscriptional regulator that belongs to the Hu/ELAV family. HuR expression levels are modulated by a variety of proteins, microRNAs, chemical compounds, or the microenvironment, and in turn, HuR affects mRNA stability and translation of various genes implicated in breast cancer formation, progression, metastasis, and treatment. The aim of the present review is to critically summarize the role of HuR in breast cancer development and its potential as a prognosticator and a therapeutic target. In this aspect, all the existing English literature concerning HuR expression and function in breast cancer cell lines, *in vivo* animal models, and clinical studies is critically presented and summarized. HuR modulates many genes implicated in biological processes crucial for breast cancer formation, growth, and metastasis, whereas the link between HuR and these processes has been demonstrated directly *in vitro* and *in vivo*. Additionally, clinical studies reveal that HuR is associated with more aggressive forms of breast cancer and is a putative prognosticator for patients' survival. All the above indicate HuR as a promising drug target for cancer therapy; nevertheless, additional studies are required to fully understand its potential and determine against which types of breast cancer and at which stage of the disease a therapeutic agent targeting HuR would be more effective.

Neoplasia (2016) 18, 674–688

Introduction

Hu-antigen R (HuR) or embryonic lethal, abnormal vision, *Drosophila* (ELAV)-like protein 1 (ELAVL1) belongs to the Hu/ELAV family and is a ubiquitously expressed RNA-binding posttranscriptional regulator [1]. Early studies performed using the neuronal-specific HuR ortholog HuB demonstrated that members of the Hu/ELAV family contain three highly conserved RNA-binding domains that belong to the RNA recognition motif (RRM) superfamily [2]; RRM-1 and RRM-2 bind to AU-rich elements, whereas RRM-3 binds to the poly(A) tail of rapidly degrading mRNAs [3]. Similarly, a U-rich sequence approximately 17 to 20 nucleotides (nt) long, usually located within the 3'-untranslated region (UTR) of the target mRNAs, has been identified as the RNA motif recognized by HuR [4]. HuR binds to this motif and regulates the stability, translation, and nucleocytoplasmic translocation of target mRNAs. More specifically, HuR binding may stabilize the

mRNA, indirectly increasing protein production [5–8], whereas its direct effect on translation efficiency can be either positive or negative [9,10]. Moreover, mRNA exon-intron splicing and polyadenylation, processes taking place in the nucleus, can also be modulated by HuR [11–14]. Additionally, HuR can be transported from the nucleus, where is most abundantly localized, to the cytoplasm, along with

Address all correspondence to: Ioly Kotta-Loizou, Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London SW7 2AZ, United Kingdom.
E-mail: i.kotta-loizou13@imperial.ac.uk
Received 1 July 2016; Revised 14 September 2016; Accepted 19 September 2016

© 2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CCBY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).
1476-5586
<http://dx.doi.org/10.1016/j.neo.2016.09.002>

bound mRNA [15], and this change in subcellular localization appears to be linked to regulating HuR function [16].

The regulatory mechanisms involved in HuR expression and function have not been comprehensively studied. It appears that phosphorylation plays an important role in its subcellular localization and activity, and a number of kinases have been found to phosphorylate HuR, including serine/threonine-protein kinase Chk2 and protein kinase C delta (Table 1). Besides phosphorylation, there is also evidence for HuR methylation [17]; however, the role of this type of posttranslational modification is less well studied. HuR mRNA and protein levels are altered in response to a number of proteins and microRNAs such as miR-519 [18], hormones such as 17 β -estradiol [19], cyclic GMP-elevating agents such as nitric oxide [20], and drugs. Furthermore, HuR protein is degraded *via* the ubiquitin-proteasome system [21] and undergoes caspase-mediated cleavage during apoptosis [22].

Alterations in HuR expression levels or subcellular localization have been associated with important medical conditions, such as pathologic inflammation [23], atherosclerosis [24], tissue ischemia [25], and, most significantly, tumor formation, growth, and metastasis [26–29]. Furthermore, HuR appears to be responsible for the expression regulation of mRNAs encoding proteins involved in transcription, cell signaling, cell division cycle, apoptosis, inflammation, and stress responses [5,10,30–33], many of them cancer relevant and implicated in malignant transformation. Moreover, clinical studies show that increased HuR expression levels and cytoplasmic expression pattern correlate with malignant phenotype and poor patient prognosis in various types of cancer [34].

Breast cancer is the most commonly reported malignancy and the most common cause of cancer-related death among women. Mammary tumors are highly complex and heterogeneous, and we still lack a global understanding of the molecular mechanisms behind breast cancer origin and progression [35]. Breast cancer cells are classified as either positive or negative for the presence of each of three important receptors: estrogen receptor-alpha (ER), tyrosine kinase-type cell surface receptor HER2, and progesterone receptor. Approximately 70% of breast tumors are ER positive and depend on

estrogen for growth [36]. Therefore, ER-targeted endocrine therapies are effective for the treatment of patients with ER-positive breast tumors, and tamoxifen is the most widely used endocrine antiestrogen treatment. Interestingly, a number of studies implicate HuR in ER and HER2 expression regulation and tamoxifen resistance, suggesting that HuR may play a crucial role in breast cancer development and possibly treatment [37,38].

In the light of the above considerations, the aim of the current review is to critically summarize the role of HuR in breast cancer as illustrated by *in vitro* experiments, *in vivo* animal models, and clinical studies and to examine its potential as a therapeutic target. Initially, we present an overview of HuR expression and general function in various breast cancer cell lines. Subsequently, we examined individual gene products modulated by HuR either directly as demonstrated by physical interaction between HuR and the target mRNA or in some cases indirectly. Finally, we describe a number of HuR expression regulators including microRNAs and commonly used therapeutic drugs against breast cancer.

HuR Expression in Breast Cancer

HuR expression has been studied in a variety of breast-derived cell lines exhibiting differential degrees of malignant potential. Both MCF10A and MCF12A are nontumorigenic immortalized epithelial cell lines and are considered to be normal breast cells. The MCF7 cell line is epithelial adenocarcinoma, ER positive. The MDA-MB-231 cell line is also epithelial adenocarcinoma, ER negative, poorly differentiated, and highly tumorigenic and invasive.

HuR expression has been reported in all the above cell lines, and HuR mRNA levels in MDA-MB-231 cells are 2.5-fold higher than in MCF7 cells and 5-fold higher than in MCF10A and MCF12A cells, as shown by quantitative reverse transcriptase polymerase chain reaction [49]. HuR mRNA was also found to be more stable in MDA-MB-231 cells as compared with MCF10A cells, with its half-life increasing from 1 hour in the latter to 4 hours in the former [49]. Although HuR is mainly localized to the nucleus [50,51], immunochemical studies revealed increased cytoplasmic HuR expression in MDA-MB-231 in comparison with MCF7 cells [52], as well as in MCF7 in comparison with MCF10A cells [53]. Interestingly, Hostetter et al. report that total HuR protein levels are higher in MCF7 than in MDA-MB-231 cells [37], whereas Calaluce et al. report similar HuR protein levels in MCF7 and MDA-MB-231 cells [52].

HuR expression has been also noted in nontumorigenic immortalized epithelial HB2 [50] and HMT-3522-T4-2 [54] cells, epithelial ductal carcinoma T47D [50,54–56] and ZR-75-1 cells [57], epithelial carcinoma BT-20 [51] and Hs578T cells [58,59], and epithelial adenocarcinoma SK-BR-3 cells [38,51,54,60,61].

A number of clinical studies revealed that HuR expression levels were elevated in atypical ductal hyperplasia (ADH), ductal carcinoma *in situ* (DCIS), and ductal invasive carcinoma (DIC) when compared with healthy tissue samples [62–64]. Interestingly, cytoplasmic HuR immunoreactivity was present in less than half of DIC [65–67], DCIS, and ADH samples [64], as well as in invasive breast cancer patients that underwent paclitaxel- and anthracycline-based neoadjuvant chemotherapy (NACT) [68]. The cytoplasmic localization of HuR in histological and cytological samples of invasive breast carcinoma is evident in Figure 1.

Apart from the apparent association between increased HuR mRNA levels and cytoplasmic HuR expression and a more malignant

Table 1. Regulation of HuR Localization and Activity *via* Phosphorylation

HuR Modification Site	Kinase	Effect on ...	Ref.
Ser88	Serine/threonine-protein kinase Chk2	target RNA stability target RNA splicing	[14,39,40]
Ser100	Serine/threonine-protein kinase Chk2	target RNA stability target RNA splicing	[14,39,40]
Thr118	Serine/threonine-protein kinase Chk2 Mitogen-activated protein kinase 14	HuR localization target RNA stability target RNA splicing	[14,39,41]
Ser158	Protein kinase C alpha	HuR localization target RNA stability	[42,43]
Tyr200	Tyrosine-protein kinase JAK3	target RNA translation HuR localization	[44]
Ser202	Cyclin-dependent kinase 1	target RNA stability HuR localization	[45]
Ser221	Protein kinase C delta	HuR localization target RNA stability	[43,46,47]
Ser318	Protein kinase C delta	target RNA translation HuR localization target RNA stability	[46–48]




Figure 1. Representative immunostainings for HuR protein expression in histological and cytological samples of invasive breast carcinoma (original magnification 400 \times).

phenotype, HuR has been reported to regulate different biological processes in different cell lines.

HuR knockdown in MCF10A cells revealed that HuR plays a crucial role in cell proliferation as demonstrated by a colony formation assay, reducing the number of colonies by up to 28% and promoting premature senescence [69]. In another study, siRNA-mediated HuR silencing decreased anchorage-independent growth of malignant T-cell-amplified sequence 1 (MCT1)-transformed MCF10A cells [70]. Additionally, HuR regulates cell polarity and is responsible for the formation of the acinar structures of MCF10A cells in 3D Matrigel culture [69]. Similarly, HuR knockdown was found to significantly decrease growth of MCF7 but not MDA-MB-231 cells [57], whereas a second study confirmed this observation, reporting a 35% reduction in MCF7 cell number after siRNA-mediated HuR silencing [71]. However, in another study, HuR overexpression in MDA-MB-231 cells was shown to enhance growth rate by altering cell cycle kinetics and increasing the number of cells in G₁ (67% vs 57%) while decreasing the number of cells in the G₂/M phase (18% vs 27%) [72]. Gubin et al. also used an orthotopic xenograft mouse model and demonstrated that HuR overexpression results in significantly reduced tumor growth and mass by 90%, as confirmed by magnetic resonance imaging scans, gross photographs, and microscopy. Both tumors were classified as moderately to poorly differentiated carcinoma, but HuR-overexpressing tumors appeared to be gelatin-like capsules with a smooth, homogeneous, and glistening surface, whereas the control tumors were a solid round mass and had a heterogeneous, yellow-white surface with a necrotic center [72].

In addition, HuR knockdown reduces invasiveness of MDA-MB-231 but not MCF7 cells, as shown by a Matrigel invasion assay [57]. In confirmation, siRNA-mediated HuR silencing was shown to

decrease the invasion ability of MDA-MB-231 cells 1.4-fold, whereas HuR overexpression increases their invasion ability two-fold. Similar results were noted in BT-20 cells [73]. More recently, siRNA-mediated HuR silencing was also shown to reduce invasiveness of MDA-MB-231 cells by 72% [49].

Moreover, siRNA-mediated HuR silencing decreases the motility of BT-20 cells 1.6-fold, whereas HuR overexpression increases their motility 2.4-fold [73]. In contrast, HuR knockdown does not affect cell adhesion or migration in both MCF7 and MDA-MB-231 cells [57], and HuR overexpression does not appear to affect apoptosis in MDA-MB-231 cells or in an orthotopic xenograft mouse model [72].

HuR Target Genes

HuR exerts its effects on cell proliferation, invasion ability, and motility of mammary cell lines by regulating the expression of target genes (Table 2).

Two major types of studies have been conducted to elucidate the global profile of HuR target genes, using immunoprecipitation of ribonucleoprotein complexes and microarray analysis (RIP-Chip assay), as initially described for HuB, another member of the Hu/ELAV family [74].

The first study assessed the HuR targets in comparison with the targets of the heterogeneous nuclear ribonucleoprotein D0 (HNRNPD/AUF1) in MCT1-transformed compared with nontransformed immortalized MCF10A cells. In total, 1676 and 2072 mRNAs exhibited significantly altered binding to HuR or HNRNPD/AUF1, respectively, and 712 of these mRNAs exhibited differential binding to both proteins. Functionally, these genes are mostly associated with cell cycle regulation, signal transduction, DNA damage response, translation regulation, and angiogenesis, as demonstrated by Gene Ontology analysis. Using the KEGG pathway database, nine pathways were found to be significantly enriched in these genes: (1) cell cycle, (2) cell communication, (3) p53 signaling pathway, (4) ribosome, (5) oxidative phosphorylation, (6) purine metabolism, (7) focal adhesion, (8) ubiquitin-mediated proteolysis, and (9) regulation of actin cytoskeleton. Similarly, in the BioCarta pathway database, seven pathways were significantly enriched: (1) caspase cascade in apoptosis, (2) cyclins and cell cycle regulation, (3) Erk1/Erk2 mitogen-activated protein kinase (MAPK) signaling, (4) Erk and phosphatidylinositol 3-kinase are necessary for collagen binding in corneal epithelia, (5) role of Ran in mitotic spindle regulation, (6) phosphoinositides and their downstream targets and HIV type 1 Nef (negative effector of Fas and tumor necrosis factor [TNF]) [70]. In parallel, Mazan-Mamczarz et al. applied a similar methodology to MCF7 cells. Overall, *ca.* 9000 mRNAs were bound by HuR, and 595 of them exhibited significantly altered binding to HuR in MCT1-transformed compared with nontransformed MCF7 cells. Functional analysis revealed that these genes are implicated in cell cycle arrest, apoptosis, and angiogenesis together with pathways important for cell survival and proliferation [75]. Overall, these results support the notion that HuR plays an important role as a regulator of key gene expression during malignant transformation.

In the second type of study, HuR targets were compared in MDA-MB-231 and MCF7 cells. Three hundred ninety-five and 64 annotated genes were respectively identified as HuR targets, together with 182 genes in both cell lines. Gene Ontology analysis of the genes differentially bound by HuR in MDA-MB-231 and MCF7 cells revealed that they are implicated in epithelial cell differentiation, hormone metabolism, regulation of biological processes, blood vessel morphogenesis, anatomical structure formation, vasculature

Table 2. Effect of HuR Protein on mRNA Stability and/or Translation of Genes in Breast Cancer Cell Lines

Protein	Effect	Cell Line	Ref.
Transcription			
Estrogen receptor (ESR1)	mRNA stabilization↑	MCF7	[37,76]
Transacting T-cell-specific transcription factor GATA-3 (GATA3)	mRNA stabilization↑	MCF7 BT474	[71]
Forkhead box protein O1 (FOXO1)	mRNA stabilization↑	MDA-MB-231	[77]
Homeobox protein Hox-A5 (HOXA5)	mRNA stabilization↑	MCF7	[78]
Signal transducer and activator of transcription 3 (STAT3)	Expression *†	MCF10A †	[70]
Activator protein 1 (AP1)	Expression *†	MCF10A †	[70]
Proto-oncogenes c-fos (FOS)	Expression *†	MCF7	[79]
Myc proto-oncogene protein (MYC)	Expression *†	MCF7	[79]
Cell signaling			
Tyrosine protein kinase Yes (YES1)	Expression * (?)	MDA-MB-231	[80]
Protein Wnt-5a (WNT5A)	Translation↓	HB2 MCF7	[50]
Insulin growth factor 1 receptor (IGF1R)	Translation↓	T47D MCF10A	[55]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	mRNA stabilization↑	SK-BR-3	[38]
Calmodulin (CALM2)	mRNA stabilization↑	MCF7	[52]
Suppressor of cytokine signaling 3 (SOCS3)	Expression *†	MCF7	[79]
C-X-C chemokine receptor type 4 (CXCR4)	mRNA stabilization↑	MDA-MB-231	[81]
Cell cycle			
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	mRNA stabilization↑	MDA-MB-468	[82]
Breast cancer type 1 susceptibility protein (BRCA1)	Translation↓	MCF7, T47D	[56]
G ₁ /S-specific cyclin E1 (CCNE1)	mRNA stabilization↑	MCF7 MCF10A	[53]
Cellular tumor antigen p53 (TP53)	Expression *†	MCF10A MCF7 SK-BR-3	[60,69]
Protein phosphatase 1D (PPM1D/WIP1)	Expression *†	MCF7 SK-BR-3	[60]
Tumor protein 63-delta Np63 (TP63)	Translation↓	MCF10A	[69]
Cyclin-dependent kinase 1 (CDK1)	Expression↑	MCF10A †	[70]
Cyclin-dependent kinase 7 (CDK7)	Expression↑	MCF10A †	[70]
DNA repair protein RAD51 homolog 1 (RAD51)	Expression↑	MCF10A †	[70]
Inflammation			
Interleukin-8 (CXCL8)	mRNA stabilization↑	Hs578T	[58]
Macrophage colony-stimulating factor 1 receptor (CSF1R)	mRNA stabilization↑	BT-20 SK-BR-3	[51]
Cyclooxygenase-2 (COX2)	mRNA stabilization↑	MDA-MB-231	[83]
Cell adhesion and angiogenesis			
CD9 antigen (CD9)	mRNA stabilization↑ mRNA stabilization↓	MCF7 MDA-MB-231	[52]
Thrombospondin-1 (THBS1)	mRNA stabilization↑	MCF7 † MDA-MB-231	[72,75]
Vascular endothelial growth factor A (VEGFA)	Expression *↓ Expression *†	MDA-MB-231 MCF7	[59,72]
Platelet-derived growth factor-C (PDGF-C)	mRNA stabilization↑	MDA-MB-231	[84]
Matrix metalloproteinase-9 (MMP9)	mRNA stabilization↑	MDA-MB-231	[57]
Apoptosis			
Tumor necrosis factor ligand superfamily member 12 (TNFSF12)	Expression *†	MCF10A †	[70]
Apoptosis regulator BAX (BAX)	Expression *†	MCF10A †	[70]
Caspase-2 (CASP2)	Expression *†	MCF10A †	[70]
Others			
Eukaryotic translation initiation factor 4E-binding protein 2 (eIF4EBP2)	Expression *†	MCF10A †	[70]
Ras-related protein Rab-2 A (RAB2A)	Expression *†	MCF10A †	[70]

* The term *expression* signifies that the exact mechanism of regulation has not been elucidated.

† MCT-1-transformed cell line.

development, nucleic acid metabolism, macromolecule biosynthesis, regulation of metabolic processes, transcriptional regulation, regulation or cellular processes, and signal transduction [52].

Besides these high-throughput studies, the physical interaction of HuR with individual genes was demonstrated by immunoprecipitation. Additionally, immunoblotting, northern hybridization, quantitative polymerase chain reaction amplification, or luciferase reporter genes were all regularly used in transcription and cell signaling assays to elucidate the regulatory mechanism of gene expression.

Transcription

ER is the major mediator of the mitogenic effects of estrogen in the mammary gland [85]. HuR binds to the 3'-UTR of ER mRNA in MCF7 cells [37], and siRNA-mediated HuR silencing resulted to a downregulation of ER mRNA levels and half-life [76]. Notably, HuR phosphorylation increases its binding to the 3'-UTR of the ER mRNA; more specifically, phosphorylation at the S88, S100, and T118 sites is necessary for HuR binding to the ER 3'-UTR, as demonstrated by the use of HuR phosphorylation mutants [37].

Transacting T-cell-specific transcription factor GATA-3 is implicated in cell differentiation, whereas its expression has been correlated with ER expression in breast cancer [86]. HuR binds to the 3'-UTR of GATA-3 mRNA in MCF7 cells, whereas siRNA-mediated HuR silencing decreased GATA-3 mRNA and protein levels in MCF7 and BT474 cells, respectively. In addition, the half-life of GATA-3 mRNA was significantly reduced. Interestingly, siRNA-mediated silencing of either HuR or GATA-3 inhibited cell proliferation by 35% and 44%, respectively [71].

Forkhead box protein O1 (FOXO1) is a transcription factor implicated in response to oxidative stress, and HuR binds to the 3'-UTR of FOXO1 mRNA in MDA-MB-231 cells, stabilizing it and enhancing its half-life. SiRNA-mediated HuR silencing and HuR overexpression revealed that HuR significantly increases in FOXO1 mRNA and protein levels [77].

The homeobox protein Hox-A5 has been shown to negatively regulate angiogenesis in breast cancer [87], and HuR binds to the 3'-UTR of the Hox-A5 mRNA in MCF7 cells. Retinoic acid treatment (100 μ M) enhances the HuR-Hox-A5 mRNA interaction and subsequently increases Hox-A5 mRNA and protein levels. Induction of Hox-A5 following RA treatment is co-regulated by HuR and miR-130a, and HuR-mediated Hox-A5 regulation plays an important role in RA-induced cell death [78].

HuR also binds to the signal transducer and activator of transcription 3 and activator protein 1 mRNAs in MCF10A cells [70] and to proto-oncogenes *c-fos* and *c-myc* mRNA in MCF7 cells [68].

Cell Signaling

The nonreceptor tyrosine-protein kinase Yes belongs to the SRC subfamily and has been associated with invasion and metastasis of breast cancer cells. HuR binds to the proximal 3'-UTR (nt 1840-3174) of the Yes mRNA in MB-MDA-231 cells and appears to play a role in Yes expression regulation [80].

Protein Wnt-5a is a ligand for members of the frizzled family of seven transmembrane receptors and may either activate or inhibit canonical Wnt signaling, depending on receptor context. In breast cancer, Wnt-5a plays a role in cell migration and invasiveness, and low Wnt-5a expression levels are correlated with poor prognosis in breast cancer patients [88]. HuR binds to the AU-rich sequences in the 3'-UTR of Wnt-5a mRNA in HB2 cells. Interestingly, HuR binding does not affect Wnt-5a mRNA stability but suppresses Wnt-5a translation. The phenomenon was also studied under hypoxic conditions (1% O₂, 24 hours), which increased HuR protein levels. As expected, Wnt-5a mRNA levels remained stable during hypoxia. However, Wnt-5a protein levels were significantly reduced, and similar results were obtained in MCF7 cells [50].

Insulin-like growth factor 1 receptor (IGF1R) is a receptor tyrosine kinase which mediates actions of insulin-like growth factor 1, controlling cell proliferation. HuR binds to the IRES located in the 5'-UTR of the IGF-1R mRNA in T47D and MCF10A cells. SiRNA-mediated HuR silencing and HuR overexpression revealed that HuR represses IGF1R IRES activity. Interestingly, HuR competes with the heterogeneous nuclear ribonucleoprotein C (hnRNP C) for binding to the IGF1R 5'-UTR, and the two proteins exert opposite effects on IGF-1R IRES activity. Amino acid deprivation (16 hours) of T47D cells downregulates HuR protein levels but increases HuR binding to IGF-1R IRES and reduces IRES activity, whereas induced G₂/M cell cycle arrest (nocodazole,

100 ng/ml, 24 hours) upregulates HuR protein levels but reduces HuR binding and increases IRES activity [55].

Receptor tyrosine-protein kinase *erbB-2*, alternatively known as tyrosine kinase-type cell surface receptor HER2 or proto-oncogene Neu, is a protein tyrosine kinase. HuR binds to the U-rich sequence (nt 465-505) in the 3'-UTR of the *erbB2* mRNA in SK-BR-3 cells. SiRNA-mediated HuR silencing results in a decrease of *erbB2* mRNA and protein levels [38].

Calmodulin is a regulatory protein that has been shown to interact with ER, probably exerting an inhibitory effect [89]. HuR binds to the 3'-UTR of the calmodulin mRNA. SiRNA-mediated HuR silencing and HuR overexpression revealed that HuR increases CALM2 mRNA and protein levels in MCF7 cells [52].

Suppressor of cytokine signaling 3 (SOCS3) is involved in negative regulation of cytokines and HuR binds to the (SOCS3) mRNA in MCF7 cells [79].

C-X-C chemokine receptor type 4 (CXCR-4) is a G-protein-coupled chemokine receptor overexpressed in breast cancer and is involved in metastasis, invasion, and migration of breast cancer cells. HuR binds to the 3'-UTR of CXCR-4 mRNA in MDA-MB-231 cells. SiRNA-mediated HuR silencing resulted in a 50% reduction of CXCR-4 mRNA and protein levels. Both HuR and CXCR-4 expression levels were low in normal tissues and higher in invasive ductal and lobular breast carcinoma ones. Similar results were noted in MCF10A, MCF12A, MCF7, and MDA-MB-231 cells, with the MDA-MB-231 cells expressing 2-fold higher CXCR-4 mRNA levels in comparison with MCF7 cells and more than a 40-fold and a 130-fold higher CXCR-4 mRNA levels as compared with the normal MCF10A and MCF12A cells, respectively. CXCR4 protein levels are also higher in MDA-MB-231 cells as compared with MCF10A. Moreover, CXCR-4 mRNA was more stable in MDA-MB-231 cells as compared with MCF10A cells. SiRNA-mediated silencing of both CXCR-4 and HuR has significant inhibitory effects on invasion and migration of MDA-MB-231 cells [81].

Tribbles-homolog 3 (TRB3) is a kinase-like protein implicated in stress response. SiRNA-mediated silencing of HuR in MCF7 cells under anoxic conditions (48 hours) reduced TRB3 mRNA by 2.4-fold and its half-life by 51% with a concomitant decrease in TRB3 protein levels [90].

Cell Cycle

Cyclin-dependent kinase inhibitor 1 (p21) plays an important role in cell cycle progression and acts as an inhibitor of cellular proliferation in response to DNA damage. HuR interacts with the 3'-UTR of the p21 mRNA in MB-MDA-468 cells. More specifically, HuR binds to the AU-rich WAF1-HuR sequence (nt 657-698) within the WAF1-1/6 region (nt 571-829) of the p21 mRNA. HuR binding was reported to increase after exposure of the cells to short-wavelength ultraviolet light (254 nm, 20 J/m², 6 hours), a mediator of p21 mRNA stability [91], and, under the same conditions, an approximately 70% upregulation of p21 mRNA stability [82]. In addition, HuR knockdown decreases p21 protein levels in MCF10A cells [69]. This constitutes a posttranscriptional mechanism of regulation of p21 expression levels in contrast to its transcriptional regulation by p53.

Breast cancer type 1 susceptibility protein (BRCA1) plays a central role in DNA repair by facilitating cellular responses to DNA damage. Notably, BRCA1 gene mutations comprise the most important genetic susceptibility factor for breast cancer. HuR binds to the

3'-UTR (nt 281-315) of the BRCA1 mRNA in MCF7 and T47D cells. Further experiments in HeLa cells indicate that HuR negatively regulates BRCA1 protein levels, with no effect on mRNA levels or stability [56].

G1/S-specific cyclin E1 plays a crucial role in the regulation of cell cycle progression and cell proliferation. Full-length cyclin E1 together with its functional, hyperactive, low-molecular weight isoforms is overexpressed in breast cancer, and HuR binds to the 3'-UTR of cyclin E1 mRNA in both MCF7 and MCF10A cells. SiRNA-mediated HuR silencing in MCF7 cells significantly decreased the half-life of cyclin E1 mRNA, and concomitantly, full-length cyclin E1 protein levels were reduced by 22% and the low-molecular weight isoforms by 80%. As a result, G₁/S cell cycle arrest was noted using flow cytometry, and cell cycle progression and cell proliferation were subsequently restored by overexpression of the low-molecular weight cyclin E1 isoforms. Similarly, HuR overexpression in MCF10A cells both increased cyclin E1 mRNA half-life and doubled protein levels [53]. Cold-inducible RNA-binding protein (CIRBP), which is negatively regulated by HuR while positively affecting HuR protein levels, also increases HuR binding to cyclin E1 mRNA, enhancing its stability [92]. Additionally, a recent study demonstrated that miR-16 blocks HuR-mediated upregulation of cyclin E1 in MCF7 cells [93].

The cellular tumor antigen p53 acts as a tumor suppressor by inducing growth arrest or apoptosis. HuR binds to p53 mRNA in MCF7 and SK-BR-3 cells, enhancing its expression [60]. In addition, HuR knockdown decreases p53 protein levels in MCF10A cells [69]. Interestingly, cytoplasmic HuR expression pattern has been significantly associated with positive p53 immunostaining in familial non-BRCA1/2 patients [94].

Protein phosphatase 1D (PPM1D/WIP1) is implicated in p53-dependent checkpoint-mediated cell cycle arrest, and HuR binds to PPM1D/WIP1 mRNA in MCF7 and SK-BR-3 cells, enhancing its expression [60].

Isoforms of tumor protein 63, designated as delta Np63, are known to suppress cell proliferation. HuR binds to U-rich elements (nt 4010-4220 and nt 4640-4868) in the 3'-UTR of the delta Np63 mRNA in MCF10A cells. HuR knockdown has little effect of delta Np63 mRNA levels but increases protein levels of delta Np63p and its target, growth arrest and DNA damage-inducible protein GADD45 alpha. Delta Np63 knockdown revealed that delta Np63 partly mediates HuR knockdown-induced growth suppression and premature senescence in MCF10A cells [69].

Moreover, HuR modulates the expression of other gene products implicated in cell cycle regulation and DNA damage response. More specifically, HuR binds the cyclin-dependent kinase 1 (CDK1), cyclin-dependent kinase 7 (CDK7), and DNA repair protein RAD51 homolog 1 (RAD51) mRNAs in MCF10A cells. SiRNA-mediated HuR silencing reduced protein levels of all the above genes [70].

Finally, HuR knockdown correlates with downregulated G₁/S-specific cyclin-D1 mRNA and protein levels in MCF7 but not MDA-MB-231 cells [57].

Inflammation

Interleukin (IL)-8 is a chemokine that promotes malignant phenotype and metastasis in breast cancer, while being produced by tumor cells as a response to other inflammatory cytokines in the tumor microenvironment [95]. In addition, IL-8 is a strong inducer of angiogenesis, and it mediates endothelial cell chemotaxis and

proliferation *in vitro* and angiogenic activity *in vivo* [96]. HuR binds to the proximal 3'-UTR of IL8 mRNA in IL1-beta-stimulated Hs578T cells. Stimulation with IL1-beta (5 ng/ml, 6-24 hours) also resulted in a time-dependent induction of IL-8 mRNA and protein levels and stabilization of IL-8 mRNA. Taken together, these observations suggest that HuR contributes to IL-8 mRNA stabilization [58].

Macrophage colony-stimulating factor 1 receptor (CSF-1-R), alternatively known as proto-oncogene c-fms, is associated with cell proliferation, metastasis, and poor survival [97]. A statistically significant association between high nuclear and cytoplasmic HuR and high cytoplasmic CSF-1-R expression levels has been observed. HuR binds to a 69-nt element which contains 5 "CUU" motifs within the 3'-UTR of CSF-1-R mRNA in BT-20 and SK-BR-3 cells. Site-directed mutagenesis confirmed the necessity of these motifs for binding [51]. Interestingly, vigilin, a regulator of lipid metabolism, also binds to the same 69-nt element competing with HuR and exerting negative effects on CSF-1-R mRNA and protein levels [73]. SiRNA-mediated HuR silencing and HuR overexpression revealed that HuR increases CSF-1-R RNA and protein levels in both BT-20 and SK-BR-3 cells, respectively. In addition, glucocorticoid stimulation of CSF-1-R expression is largely dependent on the presence of HuR [51].

Cyclooxygenase (COX)-2, also known as prostaglandin G/H synthase 2 (PTGS2), is responsible for the production of inflammatory prostaglandins. HuR binds to COX-2 mRNA in MDA-MB-231 cells. As a result, COX-2 mRNA is stabilized [83]. Interestingly, increased HuR protein levels were significantly associated with increased COX-2 expression in DIC patients [66].

Cell Adhesion and Angiogenesis

CD9 antigen is implicated in cell adhesion and cell motility, together with tumor metastasis. HuR binds to the 3'-UTR of the CD9 mRNA and differentially regulates its mRNA and protein levels in MDA-MB-231 and MCF7 cells. More specifically, siRNA-mediated HuR silencing and HuR overexpression revealed that HuR decreases CD9 mRNA and protein levels in MDA-MB-231 cells while increasing CD9 mRNA and protein levels in MCF7 cells [52].

The angiogenesis inhibitor thrombospondin-1 (THBS1) is a glycoprotein functioning as a tumor suppressor [98]. THBS1 plasma levels have been positively correlated with breast cancer progression [99]. HuR binds to the terminal the 3'-UTR of THBS1 mRNA in MCF10A and MDA-MB-231 cells [72,75]. SiRNA-mediated HuR silencing and HuR overexpression revealed that HuR modulates THBS1 protein levels. More specifically, a two-fold decrease or increase of THBS1 protein levels was noted in HuR-silenced and HuR-overexpressing MCF7 cells, respectively. Interestingly, the association between HuR and THBS1 mRNA was reduced by 65% to 85% in MCT1-transformed MCF7 cells [75]. HuR-overexpressing tumors in an orthotopic xenograft mouse model exhibited increased THBS1 mRNA (5.44-fold) and protein (76%) levels [72].

Vascular endothelial growth factor A (VEGF-A) is a growth factor involved in angiogenesis. HuR was shown to bind to VEGF-A mRNA in MDA-MB-231 cells. Surprisingly, HuR-overexpressing tumors in orthotopic mice exhibited decreased VEGF-A mRNA (2.6-fold) and protein (23%) levels with no alteration in stability [72].

Platelet-derived growth factor (PDGF)-C plays an important role in cell proliferation and migration, and its expression has been associated with poor prognosis in breast cancer patients. HuR and PDGF-C expression levels have been correlated in mammary cell lines and breast cancer patients, and direct binding of HuR to the 3'-UTR of the PDGF-C mRNA has been demonstrated. SiRNA-mediated HuR silencing confirmed the stabilization of PDGF-C mRNA by HuR in MDA-MB-231 cells. HuR-mediated upregulation of PDGF-C appears to be involved in the responses against ultraviolet irradiation (30 J/m²) and oxidative stress (H₂O₂, 800 μM, 24 hours) in MCF7 cells [84].

Matrix metalloproteinase (MMP)-9 plays an essential role in local proteolysis of extracellular matrix and cell migration. MMP-9 is overexpressed in breast cancer and has been associated with metastasis [100]. HuR knockdown correlates with reduced MMP-9 mRNA and protein levels in MDA-MB-231 but not in MCF7 cells [57].

Hypoxia-induced factor 1 alpha (HIF-1-alpha) is the main transcriptional regulator in response to hypoxic conditions, facilitating metabolic adaptation to hypoxia and playing a crucial role in tumor angiogenesis, with increased HIF-1-alpha expression levels associated with poor patient survival [101]. SiRNA-mediated silencing of HuR reduced HIF-1-alpha protein levels in MCF7 and Hs578T cells [59].

Apoptosis

HuR positively regulates the expression of gene products promoting programmed cell death. Analytically, HuR binds the tumor necrosis factor ligand superfamily member 12 (TNFSF12), apoptosis regulator BAX, caspase-2 (CASP2) mRNAs in MCF10A cells. SiRNA-mediated HuR silencing reduced protein levels of these genes [70].

Others

Finally, HuR is implicated in the expression regulation of gene products involved in translation, such as the eukaryotic translation initiation factor 4E-binding protein 2 (eIF4EBP2) and the CIRBP, and in protein transport from the endoplasmic reticulum to the Golgi complex, namely, the Ras-related protein Rab-2A (RAB2A). More specifically, HuR binds the eIF4EBP2 and RAB2A mRNAs in MCF10A cells, and siRNA-mediated HuR silencing reduced protein levels of these genes [70]. SiRNA-mediated HuR silencing increases both CIRBP mRNA and protein levels by two-fold in MCF7 cells [92].

HuR Modulators

A number of environmental conditions, proteins, microRNAs, and drugs have been shown to directly or indirectly modulate HuR expression and activity in mammary cell lines (Table 3).

Ultraviolet irradiation upregulates HuR protein levels in MCF7 cells in a dose-dependent manner [84]. Furthermore, anoxia (<0.01% O₂) increases cytoplasmic HuR expression levels in MCF7 cells. More specifically, a significant translocation of the nuclear HuR to the cytoplasm after 12 hours of anoxic incubation, and translocation of majority of HuR to the cytoplasm after 24 hours was noted [90]. In addition, oxidative stress (H₂O₂, 800 μM, 24 hours) and induced G₂/M cell cycle arrest (nocodazole, 100 ng/ml, 24 hours) upregulate HuR protein levels, whereas amino acid deprivation (16 hours) downregulates HuR protein levels [55,84].

Proteins Modulating HuR Expression

BRCA1-IRIS is a product of the BRCA1 locus, the expression of which is associated with breast cancer aggressiveness [103].

SiRNA-mediated BRCA1-IRIS silencing and BRCA1-IRIS overexpression revealed that BRCA1-IRIS increases total and cytoplasmic, but not nuclear, HuR expression levels in MCF7 and SK-BR-3 cells. The exact mechanism was not elucidated, but it probably involves nuclear factor-κappaB [60], which is known to activate HuR transcription [104]. Moreover, BRCA1-IRIS was shown to increase HuR binding to p53 and PPM1D, enhancing their expression [60].

CIRBP is a stress response translation activator, overexpressed in breast cancer [105], which may promote cell immortalization. SiRNA-mediated CIRBP silencing and CIRBP overexpression revealed that CIRBP positively regulates HuR protein levels and increases HuR-containing cytoplasmic stress granules in MCF7 cells. However, CIRBP induces no changes to HuR mRNA levels or nuclear-to-cytoplasmic ratio [92].

Heat-shock factor protein 1 (HSF-1) is a transcription factor known to be involved in breast cancer progression and metastasis [106]. SiRNA-mediated HSF-1 silencing downregulates HuR mRNA and protein levels in MCF7 and Hs578T cells. A reduction of HuR mRNA and protein levels was also noted in a HSF-1 knockdown MCF7 xenograft mouse model. Because HuR mRNA stability is not affected, HSF-1 probably modulates HuR at the level of transcription. In addition, HSF-1 knockdown results in downregulation of a number of known HuR targets in MCF7 and Hs578T cells, such as HIF-1-alpha, HIF-2-alpha, also known as endothelial PAS domain-containing protein 1 (EPAS-1), VEGF-A, p53, G2/mitotic-specific cyclin-B1, and NAD-dependent protein deacetylase sirtuin-1 (SIRT1), and represses tumor growth and angiogenesis *in vivo* [59].

Tristetraproline (TTP), similar to HuR, is an RNA-binding protein that posttranscriptionally regulates gene expression. TTP binds HuR mRNA in MDA-MB-231 cells, negatively regulating HuR mRNA levels. TTP itself is negatively modulated by miR-29a, which binds to the 3'-UTR of TTP mRNA. An abnormally low TTP:HuR ratio is noted in invasive ductal and lobular carcinomas as compared with normal breast tissue. The low TTP:HuR ratio, together with enhanced miR-29a expression, is also evident in MDA-MB-231 cells in comparison with MCF10A, MCF12A, and MCF7 cells. MiR-29a expression in MCF10A cells increases HuR mRNA levels 5-fold while reducing TTP mRNA levels by 40%, resulting in the abnormally low TTP:HuR ratio. Conversely, miR-29a inhibition in MDA-MB-231 cells decreases HuR mRNA levels by 4-fold, while enhancing TTP mRNA levels 2-fold. It also downregulates HuR targets urokinase-type plasminogen activator, MMP-1 (also known as interstitial collagenase), and MMP-13 (also known as collagenase 3) at both the mRNA and protein level and reduces cell invasiveness by 64% [49].

MicroRNAs Modulating HuR Expression

MiR-125 binds to the 3'-UTR (nt 686-692) of HuR mRNA and represses its translation, and an inverse correlation was observed between HuR protein level and miR-125 expression levels in MCF10A, MCF7, T47D, SK-BR-3, and HMT-3522-T4-2 cells. MCF10A cells have lower HuR protein levels and higher miR-125 levels than the other cell lines, whereas high levels of both HuR and miR-125 were noted in MDA-MB-231 cells. MiR-125a and b reduce HuR protein levels in MCF7 and T47D cells, miR-125a slightly decreases HuR protein levels in MCF10A cells, whereas neither miR-125a nor miR-125b affects HuR protein levels in MDA-MB-231 cells. Further studies revealed that, in MCF7 cells,

Table 3. Effect of HuR Modulators on HuR Expression and Function in Breast Cancer Cell Lines

Regulators	Effect on HuR	Cell Line	Ref.
Environmental conditions			
G ₂ /M cell cycle arrest	HuR protein levels↑	T47D	[55]
Amino acid deprivation	HuR protein levels↓	T47D	[55]
Anoxia (<0.01% O ₂)	HuR shuttling↑	MCF7	[90]
Ultraviolet irradiation	HuR protein levels↑	MCF7	[84]
Oxidative stress	HuR protein levels↑	MCF7	[84]
Proteins			
Breast cancer type 1 susceptibility protein (BRCA1)-IRIS	HuR transcription↑	MCF7 SK-BR-3	[60]
Mitogen-activated protein kinase 8 (MAPK8)	HuR shuttling↑	MCF7 MDA-MB-231	[37,102]
Cold-inducible RNA-binding protein (CIRBP)	HuR protein levels↑	BT474	[92]
Heat-shock factor protein 1 (HSF1)	HuR transcription↑	MCF7	[59]
Protein kinase C (PKC) delta	HuR shuttling↑	Hs578T MCF7	[61,79]
Tristetraproline (TTP)	HuR mRNA levels↓	MCF10A MCF12A MCF7	[49]
Epidermal growth factor receptor (EGFR)	HuR binding↑	MDA-MB-231 MDA-MB-231	[83]
microRNAs			
miRNA-125	HuR translation↓	MCF10A MCF7	[54]
miRNA-16	HuR translation↓	T47D	[63]
miRNA-29a	HuR mRNA levels↑	MDA-MB-231 MCF10A	[49]
miRNA-7	HuR binding↓	MDA-MB-231	[83]
Drugs			
Trichostatin A (TSA, 100 ng/ml)	HuR shuttling↓	MCF7 MDA-MB-231	[37,76,102]
5-aza-2'-deoxycytidine (AZA, 2.5 μM)	HuR shuttling↓	MCF7 MDA-MB-231	[37,76,102]
Tamoxifen (2.5 μM)	HuR shuttling↑	MCF7 MDA-MB-231	[37,102]
Doxorubicin (10 μM)	HuR shuttling↑	BT474	[61,79]
5-Fluorouracil (5-FU)	HuR mRNA↑	MCF7 MDA-MB-231	[77]

miR-125a represses the HuR target cyclin-E1 expression levels, together with cell proliferation by 72% and migration by 62%, in an HuR-dependent manner [54].

MiR-16 was predicted to bind to the 3'-UTR (nt 1881-1901) of HuR mRNA in MDA-MB-231 cells, downregulating HuR protein but not mRNA levels. As a result, the mRNA levels of HuR target genes, such as COX-2, SIRT1 and c-fos, were also affected. Seventy-seven percent (10 out of 13) of samples derived from invasive ductal breast carcinoma patients exhibited 1.5- and 8.5-fold increases of HuR mRNA and protein levels, respectively in tumor tissues when compared with normal tissues. In contrast, a 37% decrease of miR-16 levels in tumor tissues was noted [63].

Drugs Modulating HuR Expression and Function

Tamoxifen is a drug that targets ER signaling and is widely used in breast cancer treatment. Trichostatin A (TSA) and 5-aza-2'-deoxycytidine (AZA) are inhibitors of histone deacetylation and DNA methylation, respectively. They are used to restore ER expression in ER-negative mammary tumors, sensitizing them to tamoxifen treatment. Surprisingly, they have the opposite effect on ER-positive cell lines, reducing ER expression levels [107]. Treatment with AZA (2.5 μM, 96 hours) and TSA (100 ng/ml, 16 hours) represses MAPK8 phosphorylation and activity, resulting in increased nuclear-to-cytoplasmic HuR expression ratio and decreased ER protein expression in MCF7 cells. Reduced cytoplasmic HuR

expression levels were also noted in MDA-MB-231 cells, whereas total HuR protein levels appear slightly downregulated in MCF7 but not in MDA-MB-231 cells [37,76]. In contrast, tamoxifen treatment (2.5 μM) activates MAPK8, increasing cytoplasmic HuR expression levels in MCF7 and MDA-MB-231 cells [37,102]. Inhibition of MAPK8 in tamoxifen-sensitive MCF7 cells and tamoxifen-resistant BT474 cells resulted in reduced proliferation and increased sensitivity to tamoxifen. SiRNA-mediated HuR silencing in both MCF7 and BT474 cells and HuR overexpression in MCF7 cells revealed that HuR plays a role in tamoxifen resistance [37]. Finally, MDA-MB-231 cells were treated simultaneously with AZA, TSA, and tamoxifen. When tamoxifen is added together with TSA, cytoplasmic HuR expression levels are increased, but when they are administered separately, cytoplasmic HuR expression levels are reduced [102].

Doxorubicin is a widely used chemotherapeutic agent. Doxorubicin treatment (10 μM) induces HuR phosphorylation and subsequent nucleocytoplasmic shuttling in MCF7 cells and promotes HuR binding to its targets, such as c-fos, c-myc, and SOCS3 [79]. More specifically, doxorubicin activates protein kinase C delta, which phosphorylates HuR on serines 221 and 318 [46,61]. In contrast, HuR protein levels are reduced in doxorubicin-resistant MCF7 and MDA-MB-231 cells, and HuR cellular localization is not affected by doxorubicin treatment in MCF7 doxorubicin-resistant cells [79]. SiRNA-mediated HuR silencing and inhibition of HuR

phosphorylation by the use of rottlerin revealed that doxorubicin-induced apoptosis is HuR dependent [79].

Lapatinib (GW-572,016), an oral dual tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), has proved effective for the treatment of advanced HER2-positive breast cancer patients. In contrast, lapatinib treatment of triple-negative EGFR-overexpressing breast cancer patients enhances migration and invasion, resulting in a worse clinical outcome [108]. A series of experiments using siRNA-mediated gene silencing revealed that lapatinib treatment (1 μ M) of MDA-MB-231 cells downregulates miR-7, resulting in upregulation of EGFR mRNA and protein levels. Subsequently, EGFR interacts with HuR and enhances HuR binding to COX-2 mRNA, which is then stabilized. Finally, upregulated COX-2 expression levels lead to increased migration and invasion of MDA-MB-231 cells *in vitro* and in orthotopic mice [83].

5-Fluorouracil (5-FU) is a pyrimidine analogue used as anticancer therapeutic agent. 5-FU increases HuR mRNA and protein levels in MDA-MB-231 cells in a dose-dependent manner. Similarly, HuR target FOXO1 expression levels are also upregulated and HuR-mediated modulation of FOXO1 plays a critical role in 5-FU-induced apoptosis [77].

Clinical Significance of HuR Expression

Clinical studies in DIC patients revealed a statistically significant association between elevated total HuR expression and advanced tumor histological grade and HER2-negative status [56]. Furthermore, nuclear HuR expression pattern was positively associated with histological grade in invasive breast carcinoma patients [66], whereas cytoplasmic HuR expression pattern was correlated with advanced patients' age and tumor histological grade in carcinoma cases [65], with increased tumor grade in DCIS [64] and in invasive breast carcinomas [66,68], and with increased histological grade and ductal tumor type in familial non-BRCA1/2 cases [94] and in invasive carcinoma patients receiving NACT [64]. Moreover, it correlated with PR-negative status in DCIS [64], in familial non-BRCA1/2 cases [94], and in invasive carcinoma patients receiving NACT [68] and with ER-negative status in familial non-BRCA1/2 cases [94] and in invasive carcinoma patients receiving NACT [68]. In contrast, cytoplasmic HuR expression pattern was associated with PR-, ER- and HER2-positive status [65]. With reference to the role of HuR as a prognosticator in breast cancer patients, low total HuR expression was identified as an independent prognostic factor for reduced survival rate in DIC patients [57,62]. Additionally, high cytoplasmic HuR immunopositivity is an independent prognosticator for reduced

Table 4. Clinical Significance of HuR Expression in Breast Cancer Patients

Type of Neoplasia	Patient Samples	HuR Localization		HuR Associations & Prognostic Value			Ref.
		Nuclear	Cytoplasmic	Total	Nuclear	Cytoplasmic	
ADH	71		35/71 (47%)				[64]
DCIS	74		35/74 (49%)			↑ tumor grade ↑ aggressiveness PR(-)	[64]
DIC	82	63/82 (77%)	38/82 (46%)			↑MDR1 ↑ age ↑ histological grade PR(+) ER(+) HER2(+) ↓ survival ^{†,‡}	[65]
	13			↓ miR-16			[63]
	97			↑ tumor grade HER2(-)			[56]
	89			↑ bioenergetic phenotype ↑ survival ^{‡,§}			[62]
	133	132/133 (100%)	53/133 (40%)			↓ survival ^{†,‡}	[67]
	208	128/208 (61%)	63/208 (30%)		↑ histological grade ↑ COX-1 ↑ COX-2	↑ COX-2	[66]
	623		268/623 (43%)			↑ histological grade* ↑ ductal tumor type* PR(-)* ER(-)* ↑ p53 ↓ survival ^{†,‡}	[94]
IC + NACT	143			↑ survival ^{‡,§}			[57]
	139		60/139 (42%)			↑ DIC ↑ tumor grade ↑ histological grade PR(-) ER(-) ↓ survival ^{†,‡}	[68]

Abbreviation: IC, invasive carcinoma.

* In familial non-BRCA1/2 cases.

† Overall survival.

‡ Disease-free survival.

§ Progression-free survival.

survival rate in DIC patients [65,67], invasive carcinoma patients receiving NACT [68], and familial non-BRCA1/2 patients [94] (Table 4).

Conclusion

In total, HuR has been confirmed to bind to 38 protein-coding mRNAs in mammary cell lines, summarized in Table 2, modulating their expression posttranscriptionally. In the majority of the cases and as anticipated, HuR stabilizes the target mRNA. Surprisingly though, CD9 antigen mRNA levels were downregulated in MDA-MB-231 HuR-overexpressing cells and upregulated following siRNA-mediated HuR silencing [52], indicating that HuR may also exert a

destabilizing effect. HuR is also known to affect translation, suppressing Wnt-5a [50], delta Np63 [69], IGF-1-R [55], and BRCA1 [56] protein production. There are also a number of genes modulated by HuR for which the regulatory mechanism has not been elucidated, at least in mammary cell lines. Some of them have been studied extensively in other systems; for example, HuR is known to enhance p53 translation in colorectal carcinoma cells [75]. In addition, HuR is responsible for the expression regulation of another seven genes, although direct binding of HuR to the mRNAs was not demonstrated in mammary cell lines. Again, four out of seven of these genes, CCNB1, HIF1, HIF2, and PLAU, are known HuR targets, modulated at the mRNA stability level [33,109–111].




Figure 2. Schematic representation of the regulatory axes mediated by HuR in breast cancer cells. HuR is the wide rectangle in the middle of the cartoon. All shapes above the rectangle are proteins, miRNAs, drugs, and environmental conditions regulating HuR expression and function. All shapes below the rectangle are genes regulated by HuR. Blue arrows indicate positive regulation; red horizontal lines indicate negative regulation; dotted lines signify the lack of known direct binding of HuR on the target gene in breast cancer cells. The wide colored arrows point to biological processes experimentally proven to be affected by these regulatory axes.

Of particular interest are gene products differentially regulated by HuR in breast cancer cell lines representing various tumor progression stages, and HuR appears to exert opposite effects on VEGF-A in MCF7 and MDA-MB-213 cells. More specifically, HuR was observed to upregulate VEGF-A protein levels in nonmetastatic MCF7 cells [59], possibly by stabilizing its mRNA as reported previously [112]. In contrast, in an *in vivo* mouse model xenografted with MDA-MB-231 cells, HuR repressed VEGF-A protein levels [72]. Another gene product differentially regulated in MCF7 and MDA-MB-213 cells is CD9 antigen [52].

The majority of genes modulated by HuR are implicated in biological processes such as cell proliferation, invasion, and migration, together with angiogenesis and tumor growth. Additionally, the link between HuR and these processes has been demonstrated directly in some of the studies reported here, verifying the importance of HuR expression and function in breast cancer progression (Figure 2). Interestingly, HuR promotes growth in the nontumorigenic MCF10A cells and in the ER-positive MCF7 cells, as illustrated both by direct proliferation assays [57,69,71] and by the regulation of genes involved in cell cycle (Table 2). In contrast, HuR has little effect on the growth of the ER-negative, highly tumorigenic MDA-MB-231 cells; however, it appears to be at least partly responsible for their invasive phenotype [49,73]. Regarding apoptosis, HuR upregulates proapoptotic genes in MCT-1-transformed MCF10A cells (Table 2) but has no effect on MDA-MB-213 cells [72]. Figure 3 summarizes the HuR-mediated differential regulation of important biological processes in different cell lines.

Moreover, a number of clinical studies in breast cancer patients demonstrate that HuR is significantly correlated with advanced clinicopathological parameters, indicating that high HuR expression levels may constitute an aggravating factor for tumor growth and metastasis. Furthermore, a cytoplasmic HuR expression pattern appears to be an independent prognostic factor for reduced breast cancer patients' survival. This observation is in agreement with clinical studies in other cancer types [34].

Because HuR appears to be a common denominator and regulator for a number of pathways crucial for tumor formation, growth, and metastasis; is implicated in chemoresistance mechanisms to therapeutic drugs, such as tamoxifen; and is associated with important potential therapeutic targets, such as cyclin D1 [113], CDK1 [114], CDK7 [115], MPP-13 [116], and YES1 [117], it is feasible that HuR itself could constitute a possible drug target for cancer therapy. Targeting HuR would likely mitigate the severity of the disease and delay progression, and because HuR is implicated in multiple cancer-related pathways, it should be possible to simultaneously block at least a few if not all of them using therapeutic agents that act *via* HuR. Interestingly, HuR is implicated in retinoic acid-, doxorubicin-, and 5-FU-mediated apoptosis [77–79], suggesting another possible mode of action for the prospective therapeutic drugs. Future studies should be focused to the discovery and development of HuR-specific drugs for treatment of breast cancer and possibly other cancer types. Recently a number of high-throughput screening methods have been established to identify low-molecular weight agents against HuR, including a confocal fluctuation spectroscopic assay [118], fluorescence polarization assays [119,120] coupled with nuclear magnetic resonance [120], and a mammalian cell based system [121]. As a result, a number of promising chemicals binding to HuR and disrupting HuR dimerization and HuR-mRNA interactions have been reported, such as MS-444, dehydromutactin, okicenone [118],




Figure 3. Proposed model on the localization and function of HuR in normal mammary cells, early-stage mammary tumors (as typified by the ER-positive MCF-7 cell line), and late-stage mammary tumors (as typified by the ER-negative MDA-MB-231 cell line). The cytoplasmic HuR expression levels are correlated with the degree of malignancy, and HuR binding to different target mRNAs leads to differential regulation of cancer-related biological processes.

quercetin, b-40, and b-41 [122], mitoxanthrone [121], CMLD-2 [119], and 15,16-dihydrotanshinone [123]. The latter, a traditional Chinese medicine, is of particular interest because it has been assessed in breast cancer cell lines and was shown to have HuR-dependent antiproliferative (1 mM) and cytotoxic (10 mM) effects in MCF-7 cells and to inhibit the migration of MDA-MB-231 cells [123]. Additionally, 15,16-dihydrotanshinone [123] and dehydromutactin [118] were noted to affect the subcellular localization of HuR, leading to increased nuclear-to-cytoplasmic HuR ratio. Similarly, apoptosis-inducing CMLD-2 was demonstrated to be preferentially cytotoxic against (colon and pancreatic) cancer cells when compared with normal cells and to suppress the oncogenic Wnt signaling [119]. All the above effects are mediated by the resulting alterations to mRNA stability and translation of various HuR target genes. Two

more of the aforementioned chemicals, MS-444 and okicenone, were already known for their properties against cancer, which are now shown to be at least partly HuR dependent [118]. Which, if any, of these compounds would be effective against breast cancer remains an open question. To this end, further investigation is required to elucidate HuR mechanisms of action and determine at which stage of the disease and against which types of breast cancer a specific therapeutic agent targeting HuR would be more effective. The construction of stable mammary cell lines for inducible HuR expression would be an initial step toward this direction prior to *in vivo* animal and clinical studies.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest

None.

References

- Ma WJ, Cheng S, Campbell C, Wright A, and Furneaux H (1996). Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. *J Biol Chem* **271**, 8144–8151.
- Burd CG and Dreyfuss G (1994). Conserved structures and diversity of functions of RNA-binding proteins. *Science* **265**, 615–621.
- Levine TD, Gao F, King PH, Andrews LG, and Keene JD (1993). Hel-N1: an autoimmune RNA-binding protein with specificity for 3' uridylyate-rich untranslated regions of growth factor mRNAs. *Mol Cell Biol* **13**, 3494–3504.
- Lopez de Silanes I, Zhan M, Lal A, Yang X, and Gorospe M (2004). Identification of a target RNA motif for RNA-binding protein HuR. *Proc Natl Acad Sci U S A* **101**, 2987–2992.
- Brennan CM and Steitz JA (2001). HuR and mRNA stability. *Cell Mol Life Sci* **58**, 266–277.
- Myer VE, Fan XC, and Steitz JA (1997). Identification of HuR as a protein implicated in AUUUA-mediated mRNA decay. *EMBO J* **16**, 2130–2139.
- Fan XC and Steitz JA (1998). Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the *in vivo* stability of ARE-containing mRNAs. *EMBO J* **17**, 3448–3460.
- Peng SS, Chen CY, Xu N, and Shyu AB (1998). RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. *EMBO J* **17**, 3461–3470.
- Kullmann M, Gopfert U, Siewe B, and Hengst L (2002). ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5'UTR. *Genes Dev* **16**, 3087–3099.
- Mazan-Mamczarz K, Galban S, Lopez de Silanes I, Martindale JL, Atasoy U, Keene JD, and Gorospe M (2003). RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. *Proc Natl Acad Sci U S A* **100**, 8354–8359.
- Zhu H, Zhou HL, Hasman RA, and Lou H (2007). Hu proteins regulate polyadenylation by blocking sites containing U-rich sequences. *J Biol Chem* **282**, 2203–2210.
- Izquierdo JM (2008). Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. *J Biol Chem* **283**, 19077–19084.
- Mukherjee N, Corcoran DL, Nusbaum JD, Reid DW, Georgiev S, Hafner M, Ascano Jr M, Tuschl T, Ohler U, and Keene JD (2011). Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. *Mol Cell* **43**, 327–339.
- Akaike Y, Masuda K, Kuwano Y, Nishida K, Kajita K, Kurokawa K, Satake Y, Shoda K, Imoto I, and Rokutan K (2014). HuR regulates alternative splicing of the TRA2beta gene in human colon cancer cells under oxidative stress. *Mol Cell Biol* **34**, 2857–2873.
- Fan XC and Steitz JA (1998). HNS, a nuclear-cytoplasmic shuttling sequence in HuR. *Proc Natl Acad Sci U S A* **95**, 15293–15298.
- Keene JD (1999). Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. *Proc Natl Acad Sci U S A* **96**, 5–7.
- Li H, Park S, Kilburn B, Jelinek MA, Henschen-Edman A, Aswad DW, Stallcup MR, and Laird-Offringa IA (2002). Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1. Coactivator-associated arginine methyltransferase. *J Biol Chem* **277**, 44623–44630.
- Abdelmohsen K, Srikantan S, Kuwano Y, and Gorospe M (2008). miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. *Proc Natl Acad Sci U S A* **105**, 20297–20302.
- Cabilla JP, Nudler SI, Ronchetti SA, Quinteros FA, Lasaga M, and Duvilanski BH (2011). Nitric oxide-sensitive guanylyl cyclase is differentially regulated by nuclear and non-nuclear estrogen pathways in anterior pituitary gland. *PLoS One* **6**, e29402.
- Akool E-S, Kleinert H, Hamada FM, Abdelwahab MH, Forstmann U, Pfeilschifter J, and Eberhardt W (2003). Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. *Mol Cell Biol* **23**, 4901–4916.
- Abdelmohsen K, Srikantan S, Yang X, Lal A, Kim HH, Kuwano Y, Galban S, Becker KG, Kamara D, de Cabo R, et al (2009). Ubiquitin-mediated proteolysis of HuR by heat shock. *EMBO J* **28**, 1271–1282.
- Mazroui R, Di Marco S, Clair E, von Roretz C, Tenenbaum SA, Keene JD, Saleh M, and Gallouzi IE (2008). Caspase-mediated cleavage of HuR in the cytoplasm contributes to pp32/PHAP-I regulation of apoptosis. *J Cell Biol* **180**, 113–127.
- Yiakouvakaki A, Dimitriou M, Karakasilotis I, Eftychi C, Theocharis S, and Kontoyiannis DL (2012). Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis. *J Clin Invest* **122**, 48–61.
- Rhee WJ, Ni CW, Zheng Z, Chang K, Jo H, and Bao G (2010). HuR regulates the expression of stress-sensitive genes and mediates inflammatory response in human umbilical vein endothelial cells. *Proc Natl Acad Sci U S A* **107**, 6858–6863.
- Zhang J, Modi Y, Yarovsky T, Yu J, Collinge M, Kyriakides T, Zhu Y, Sessa WC, Pardi R, and Bender JR (2012). Macrophage beta2 integrin-mediated, HuR-dependent stabilization of angiogenic factor-encoding mRNAs in inflammatory angiogenesis. *Am J Pathol* **180**, 1751–1760.
- Lopez de Silanes I, Lal A, and Gorospe M (2005). HuR: post-transcriptional paths to malignancy. *RNA Biol* **2**, 11–13.
- Wang J, Zhao W, Guo Y, Zhang B, Xie Q, Xiang D, Gao J, Wang B, and Chen Z (2009). The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. *Oncology* **76**, 420–429.
- Kurosu T, Ohga N, Hida Y, Maishi N, Akiyama K, Kakuguchi W, Kuroshima T, Kondo M, Akino T, Totsuka Y, et al (2011). HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. *Br J Cancer* **104**, 819–829.
- Lopez de Silanes I, Fan J, Yang X, Zonderman AB, Potapova O, Pizer ES, and Gorospe M (2003). Role of the RNA-binding protein HuR in colon carcinogenesis. *Oncogene* **22**, 7146–7154.
- Abdelmohsen K, Lal A, Kim HH, and Gorospe M (2007). Posttranscriptional orchestration of an anti-apoptotic program by HuR. *Cell Cycle* **6**, 1288–1292.
- Katsanou V, Papadaki O, Milatos S, Blackshear PJ, Anderson P, Kollias G, and Kontoyiannis DL (2005). HuR as a negative posttranscriptional modulator in inflammation. *Mol Cell* **19**, 777–789.
- Sengupta S, Jang BC, Wu MT, Paik JH, Furneaux H, and Hla T (2003). The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. *J Biol Chem* **278**, 25227–25233.
- Wang W, Caldwell MC, Lin S, Furneaux H, and Gorospe M (2000). HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. *EMBO J* **19**, 2340–2350.
- Kotta-Loizou I, Giaginis C, and Theocharis S (2014). Clinical significance of HuR expression in human malignancy. *Med Oncol* **31**, 161.
- Skibinski A and Kuperwasser C (2015). The origin of breast tumor heterogeneity. *Oncogene*.
- Wang L, Gallo KA, and Conrad SE (2013). Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis. *Oncotarget* **4**, 1158–1171.
- Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, Brody JR, and Keen JC (2008). Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. *Cancer Biol Ther* **7**, 1496–1506.
- Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schafer S, Jung M, and Benz CC (2008). Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. *Mol Cancer Res* **6**, 1250–1258.

- [39] Abdelmohsen K, Pullmann Jr R, Lal A, Kim HH, Galban S, Yang X, Blethrow JD, Walker M, Shubert J, Gillespie DA, et al (2007). Phosphorylation of HuR by Chk2 regulates SIRT1 expression. *Mol Cell* **25**, 543–557.
- [40] Yu TX, Wang PY, Rao JN, Zou T, Liu L, Xiao L, Gorospe M, and Wang JY (2011). Chk2-dependent HuR phosphorylation regulates occludin mRNA translation and epithelial barrier function. *Nucleic Acids Res* **39**, 8472–8487.
- [41] Lafarga V, Cuadrado A, Lopez de Silanes I, Bengochea R, Fernandez-Capetillo O, and Nebreda AR (2009). p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. *Mol Cell Biol* **29**, 4341–4351.
- [42] Schulz S, Doller A, Pardini NR, Wilce JA, Pfeilschifter J, and Eberhardt W (2013). Domain-specific phosphomimetic mutation allows dissection of different protein kinase C (PKC) isotype-triggered activities of the RNA binding protein HuR. *Cell Signal* **25**, 2485–2495.
- [43] Doller A, Huwiler A, Muller R, Radeke HH, Pfeilschifter J, and Eberhardt W (2007). Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. *Mol Biol Cell* **18**, 2137–2148.
- [44] Yoon JH, Abdelmohsen K, Srikantan S, Guo R, Yang X, Martindale JL, and Gorospe M (2014). Tyrosine phosphorylation of HuR by JAK3 triggers dissociation and degradation of HuR target mRNAs. *Nucleic Acids Res* **42**, 1196–1208.
- [45] Kim HH, Abdelmohsen K, Lal A, Pullmann Jr R, Yang X, Galban S, Srikantan S, Martindale JL, Blethrow J, Shokat KM, et al (2008). Nuclear HuR accumulation through phosphorylation by Cdk1. *Genes Dev* **22**, 1804–1815.
- [46] Doller A, Schlepckow K, Schwalbe H, Pfeilschifter J, and Eberhardt W (2010). Tandem phosphorylation of serines 221 and 318 by protein kinase Cdelta coordinates mRNA binding and nucleocytoplasmic shuttling of HuR. *Mol Cell Biol* **30**, 1397–1410.
- [47] Doller A, Akool el S, Huwiler A, Muller R, Radeke HH, Pfeilschifter J, and Eberhardt W (2008). Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. *Mol Cell Biol* **28**, 2608–2625.
- [48] Doller A, Winkler C, Azrilian I, Schulz S, Hartmann S, Pfeilschifter J, and Eberhardt W (2011). High-constitutive HuR phosphorylation at Ser 318 by PKC{delta} propagates tumor relevant functions in colon carcinoma cells. *Carcinogenesis* **32**, 676–685.
- [49] Al-Ahmadi W, Al-Ghamdi M, Al-Souhibani N, and Khabar KS (2013). miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. *J Pathol* **230**, 28–38.
- [50] Leandersson K, Riesbeck K, and Andersson T (2006). Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. *Nucleic Acids Res* **34**, 3988–3999.
- [51] Woo HH, Zhou Y, Yi X, David CL, Zheng W, Gilmore-Hebert M, Kluger HM, Ulukus EC, Baker T, Stoffer JB, et al (2009). Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. *Oncogene* **28**, 1176–1186.
- [52] Calaluce R, Gubin MM, Davis JW, Magee JD, Chen J, Kuwano Y, Gorospe M, and Atasoy U (2010). The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer. *BMC Cancer* **10**, 126.
- [53] Guo X and Hartley RS (2006). HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. *Cancer Res* **66**, 7948–7956.
- [54] Guo X, Wu Y, and Hartley RS (2009). MicroRNA-125a represses cell growth by targeting HuR in breast cancer. *RNA Biol* **6**, 575–583.
- [55] Meng Z, Jackson NL, Choi H, King PH, Emanuel PD, and Blume SW (2008). Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells. *J Cell Physiol* **217**, 172–183.
- [56] Saunus JM, French JD, Edwards SL, Beveridge DJ, Hatchell EC, Wagner SA, Stein SR, Davidson A, Simpson KJ, Francis GD, et al (2008). Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. *Cancer Res* **68**, 9469–9478.
- [57] Yuan Z, Sanders AJ, Ye L, Wang Y, and Jiang WG (2011). Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis. *Anticancer Res* **31**, 303–310.
- [58] Suswam EA, Nabors LB, Huang Y, Yang X, and King PH (2005). IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. *Int J Cancer* **113**, 911–919.
- [59] Gabai VL, Meng L, Kim G, Mills TA, Benjamin IJ, and Sherman MY (2012). Heat shock transcription factor Hsf1 is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR. *Mol Cell Biol* **32**, 929–940.
- [60] Chock K, Allison JM, and Elshamy WM (2010). BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells. *Oncogene* **29**, 5274–5285.
- [61] Latorre E, Castiglioni I, Gatto P, Carelli S, Quattrone A, and Provenzani A (2014). Loss of protein kinase Cdelta/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines. *J Pharmacol Exp Ther* **349**, 99–106.
- [62] Ortega AD, Sala S, Espinosa E, Gonzalez-Baron M, and Cuezva JM (2008). HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. *Carcinogenesis* **29**, 2053–2061.
- [63] Xu F, Zhang X, Lei Y, Liu X, Liu Z, Tong T, and Wang W (2010). Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. *J Cell Biochem* **111**, 727–734.
- [64] Heinonen M, Hemmes A, Salmenkivi K, Abdelmohsen K, Vilen ST, Laakso M, Leidenius M, Salo T, Hautaniemi S, Gorospe M, et al (2011). Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. *J Pathol* **224**, 529–539.
- [65] Zhu Z, Wang B, Bi J, Zhang C, Guo Y, Chu H, Liang X, Zhong C, and Wang J (2013). Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. *Tumour Biol* **34**, 2299–2308.
- [66] Denkert C, Weichert W, Winzer KJ, Muller BM, Noske A, Niesporek S, Kristiansen G, Guski H, Dietel M, and Hauptmann S (2004). Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. *Clin Cancer Res* **10**, 5580–5586.
- [67] Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, and Ristimaki A (2005). Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. *Cancer Res* **65**, 2157–2161.
- [68] Wang J, Li D, Wang B, and Wu Y (2013). Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. *Breast Cancer Res Treat* **141**, 213–224.
- [69] Yan W, Zhang Y, Zhang J, Cho SJ, and Chen X (2012). HuR is necessary for mammary epithelial cell proliferation and polarity at least in part via DeltaNp63. *PLoS One* **7**, e45336.
- [70] Mazan-Mamczarz K, Hagner PR, Dai B, Wood WH, Zhang Y, Becker KG, Liu Z, and Gartenhaus RB (2008). Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach. *Cancer Res* **68**, 7730–7735.
- [71] Licata LA, Hostetter CL, Crismale J, Sheth A, and Keen JC (2010). The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines. *Breast Cancer Res Treat* **122**, 55–63.
- [72] Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, Shaw DP, Ma L, Brown A, Hoffman T, Rold TL, et al (2010). Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. *Cell Cycle* **9**, 3337–3346.
- [73] Woo HH, Yi X, Lamb T, Menzl I, Baker T, Shapiro DJ, and Chambers SK (2011). Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer. *Mol Cell Biol* **31**, 215–225.
- [74] Tenenbaum SA, Carson CC, Lager PJ, and Keene JD (2000). Identifying mRNA subsets in messenger ribonucleoprotein complexes by using cDNA arrays. *Proc Natl Acad Sci U S A* **97**, 14085–14090.
- [75] Mazan-Mamczarz K, Hagner PR, Corl S, Srikantan S, Wood WH, Becker KG, Gorospe M, Keene JD, Levenson AS, and Gartenhaus RB (2008). Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. *Oncogene* **27**, 6151–6163.
- [76] Przybylkowski P, Obajimi O, and Keen JC (2008). Trichostatin A and 5-Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. *Breast Cancer Res Treat* **111**, 15–25.
- [77] Li Y, Yu J, Du D, Fu S, Chen Y, Yu F, and Gao P (2013). Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells. *Oncol Lett* **6**, 156–160.

- [78] Yang F, Miao L, Mei Y, and Wu M (2013). Retinoic acid-induced HOXA5 expression is co-regulated by HuR and miR-130a. *Cell Signal* **25**, 1476–1485.
- [79] Latorre E, Tebaldi T, Viero G, Sparta AM, Quattrone A, and Provenzano A (2012). Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. *Mol Cancer* **11**, 13.
- [80] Sommer S, Cui Y, Brewer G, and Fuqua SA (2005). The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells. *J Steroid Biochem Mol Biol* **97**, 219–229.
- [81] Al-Souhibani N, Al-Ghamdi M, Al-Ahmadi W, and Khabar KS (2014). Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells. *Carcinogenesis* **35**, 1983–1992.
- [82] Giles KM, Daly JM, Beveridge DJ, Thomson AM, Voon DC, Furneaux HM, Jazayeri JA, and Leedman PJ (2003). The 3'-untranslated region of p21WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein. *J Biol Chem* **278**, 2937–2946.
- [83] Hsia TC, Tu CY, Chen YJ, Wei YL, Yu MC, Hsu SC, Tsai SL, Chen WS, Yeh MH, Yen CJ, et al (2013). Lapaninib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. *Mol Pharmacol* **83**, 857–869.
- [84] Luo NA, Qu YQ, Yang GD, Wang T, Li RL, Jia LT, and Dong R (2014). Post-transcriptional up-regulation of PDGF-C by HuR in advanced and stressed breast cancer. *Int J Mol Sci* **15**, 20306–20320.
- [85] Hewitt SC, Harrell JC, and Korach KS (2005). Lessons in estrogen biology from knockout and transgenic animals. *Annu Rev Physiol* **67**, 285–308.
- [86] Hoch RV, Thompson DA, Baker RJ, and Weigel RJ (1999). GATA-3 is expressed in association with estrogen receptor in breast cancer. *Int J Cancer* **84**, 122–128.
- [87] Rhoads K, Arderiu G, Charboneau A, Hansen SL, Hoffman W, and Boudreau N (2005). A role for Hox A5 in regulating angiogenesis and vascular patterning. *Lymphat Res Biol* **3**, 240–252.
- [88] Leris AC, Roberts TR, Jiang WG, Newbold RF, and Mokbel K (2005). WNT5A expression in human breast cancer. *Anticancer Res* **25**, 731–734.
- [89] Gallo D, Jacquot Y, Laurent G, and Leclercq G (2008). Calmodulin, a regulatory partner of the estrogen receptor alpha in breast cancer cells. *Mol Cell Endocrinol* **291**, 20–26.
- [90] Rzymiski T, Paantjens A, Bod J, and Harris AL (2008). Multiple pathways are involved in the anoxia response of SKIP3 including HuR-regulated RNA stability, NF-kappaB and ATF4. *Oncogene* **27**, 4532–4543.
- [91] Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, Holbrook N, and Gorospe M (2000). HuR regulates p21 mRNA stabilization by UV light. *Mol Cell Biol* **20**, 760–769.
- [92] Guo X, Wu Y, and Hartley RS (2010). Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer. *Mol Carcinog* **49**, 130–140.
- [93] Guo X, Connick MC, Vanderhoof J, Ishak MA, and Hartley RS (2015). MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells. *Int J Mol Sci* **16**, 7112–7132.
- [94] Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomaki K, Blomqvist C, Heikkila P, Haglund C, Nevanlinna H, and Ristimaki A (2007). Prognostic role of HuR in hereditary breast cancer. *Clin Cancer Res* **13**, 6959–6963.
- [95] Todorovic-Rakovic N and Milovanovic J (2013). Interleukin-8 in breast cancer progression. *J Interferon Cytokine Res* **33**, 563–570.
- [96] Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, and Strieter RM (1992). Interleukin-8 as a macrophage-derived mediator of angiogenesis. *Science* **258**, 1798–1801.
- [97] Swierczak A, Cook AD, Lenzo JC, Restall CM, Doherty JP, Anderson RL, and Hamilton JA (2014). The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. *Cancer Immunol Res* **2**, 765–776.
- [98] Ioachim E, Damala K, Tsanou E, Briasoulis E, Papadiotis E, Mitselou A, Charhanti A, Doukas M, Lampri L, and Arvanitis DL (2012). Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. *Histol Histopathol* **27**, 209–216.
- [99] Suh EJ, Kabir MH, Kang UB, Lee JW, Yu J, Noh DY, and Lee C (2012). Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers. *Exp Mol Med* **44**, 36–44.
- [100] Mehner C, Hockla A, Miller E, Ran S, Radisky DC, and Radisky ES (2014). Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. *Oncotarget* **5**, 2736–2749.
- [101] Wang W, He YF, Sun QK, Wang Y, Han XH, Peng DF, Yao YW, Ji CS, and Hu B (2014). Hypoxia-inducible factor 1alpha in breast cancer prognosis. *Clin Chim Acta* **428**, 32–37.
- [102] Hostetter CL, Licata LA, and Keen JC (2009). Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. *Cancer Lett* **275**, 178–184.
- [103] Shimizu Y, Luk H, Horio D, Miron P, Griswold M, Iglehart D, Hernandez B, Killeen J, and ElShamy WM (2012). BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. *PLoS One* **7**, e34102.
- [104] Kang MJ, Ryu BK, Lee MG, Han J, Lee JH, Ha TK, Byun DS, Chae KS, Lee BH, Chun HS, et al (2008). NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. *Gastroenterology* **135**(2030-2042), 2042.e2031–2042.e2033.
- [105] Artero-Castro A, Callejas FB, Castellvi J, Kondoh H, Carnero A, Fernandez-Marcos PJ, Serrano M, Ramon y Cajal S, and Leonart ME (2009). Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. *Mol Cell Biol* **29**, 1855–1868.
- [106] Dai C, Whitesell L, Rogers AB, and Lindquist S (2007). Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. *Cell* **130**, 1005–1018.
- [107] Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, and Vigushin DM (2004). Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. *Clin Cancer Res* **10**, 8094–8104.
- [108] Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C, Williams LS, and Di Leo A (2009). Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. *J Clin Oncol* **27**, 3908–3915.
- [109] Tran H, Maurer F, and Nagamine Y (2003). Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. *Mol Cell Biol* **23**, 7177–7188.
- [110] Sheflin LG, Zou AP, and Spaulding SW (2004). Androgens regulate the binding of endogenous HuR to the AU-rich 3'UTRs of HIF-1alpha and EGF mRNA. *Biochem Biophys Res Commun* **322**, 644–651.
- [111] Danilin S, Sourbier C, Thomas L, Lindner V, Rothhut S, Dormoy V, Helwig JJ, Jacqmin D, Lang H, and Massfelder T (2010). Role of the RNA-binding protein HuR in human renal cell carcinoma. *Carcinogenesis* **31**, 1018–1026.
- [112] Levy NS, Chung S, Furneaux H, and Levy AP (1998). Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. *J Biol Chem* **273**, 6417–6423.
- [113] Arnold A and Papanikolaou A (2005). Cyclin D1 in breast cancer pathogenesis. *J Clin Oncol* **23**, 4215–4224.
- [114] Kang J, Sergio CM, Sutherland RL, and Musgrove EA (2014). Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. *BMC Cancer* **14**, 32.
- [115] Wang Y, Liu F, Mao F, Hang Q, Huang X, He S, Cheng C, Wang H, Xu G, Zhang T, et al (2013). Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. *J Biol Chem* **288**, 9028–9034.
- [116] Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, and Singh RK (2010). Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. *Cancer Res* **70**, 3494–3504.
- [117] Bilal E, Alexe G, Yao M, Cong L, Kulkarni A, Gijjala V, Toppmeyer D, Ganesan S, and Bhanot G (2010). Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers. *Genes Cancer* **1**, 1063–1073.
- [118] Meisner NC, Hintersteiner M, Mueller K, Bauer R, Seifert JM, Naegeli HU, Ottl J, Oberer L, Guenat C, Moss S, et al (2007). Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. *Nat Chem Biol* **3**, 508–515.
- [119] Wu X, Lan L, Wilson DM, Marquez RT, Tsao WC, Gao P, Roy A, Turner BA, McDonald P, Tunge JA, et al (2015). Identification and validation of novel small molecule disruptors of HuR-mRNA interaction. *ACS Chem Biol* **10**, 1476–1484.

- [120] Wang Z, Bhattacharya A, and Ivanov DN (2015). Identification of Small-Molecule Inhibitors of the HuR/RNA Interaction Using a Fluorescence Polarization Screening Assay Followed by NMR Validation. *PLoS One* **10**, e0138780.
- [121] D'Agostino VG, Adami V, and Provenzani A (2013). A novel high throughput biochemical assay to evaluate the HuR protein-RNA complex formation. *PLoS One* **8**, e72426.
- [122] Chae MJ, Sung HY, Kim EH, Lee M, Kwak H, Chae CH, Kim S, and Park WY (2009). Chemical inhibitors destabilize HuR binding to the AU-rich element of TNF-alpha mRNA. *Exp Mol Med* **41**, 824–831.
- [123] D'Agostino VG, Lal P, Mantelli B, Tiedje C, Zucal C, Thongon N, Gaestel M, Latorre E, Marinelli L, Seneci P, et al (2015). Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function. *Sci Rep* **5**, 16478.